2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

enzyme models

" in MedChemExpress (MCE) Product Catalog:

65

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

10

Natural
Products

2

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W055845
    4-Methylbenzamide oxime

    		Biochemical Assay Reagents Others
    4-Methylbenzamide oxime is a model of benzamide oxime and can be used as a substrate for mitochondrial amidoxime reducing component (mARC) catalytic enzyme reduction .
    4-Methylbenzamide oxime
  • HY-122604
    PF-DcpSi

    		DNA/RNA Synthesis Neurological Disease
    PF-DcpSi is a mRNA decapping scavenger enzyme (DcpS) inhibitor (IC50: 0.11 nM). PF-DcpSi (30 mg/kg,i.p.) ameliorates the disease phenotype in a mice model of spinal muscular atrophy (SMA) .
    PF-DcpSi
  • HY-138830
    TAK-418
    2 Publications Verification

    		 Histone Demethylase Neurological Disease
    TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models .
    TAK-418
  • HY-160912
    ELOVL6-IN-5

    		ELOVL Cancer
    ELOVL6-IN-5 (compound B) is an inhibitor of the elongase enzyme of long-chain fatty acid family 6 (ELOVL6). ELOVL6 is a rate-limiting enzyme for the elongation of saturated and monounsaturated long-chain fatty acids and is an effective target for inhibiting diabetes. ELOVL6-IN-5 reduces hepatic fatty acid levels in a mouse model of diet-induced obesity (DIO). However, ELOVL6 inhibition by ELOVL6-IN-5 did not improve insulin resistance .
    ELOVL6-IN-5
  • HY-114196
    Aclimostat

    ZGN-1061

    		 MetAP Metabolic Disease
    Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells .
    Aclimostat
  • HY-163346
    TPEG-P

    		Biochemical Assay Reagents Metabolic Disease
    TPEG-P is an enzyme-activated intramolecular hydrogen bond (IMHB) enhanced probe, developed for ALP detection in cells and mice models of DILI .
    TPEG-P
  • HY-A0113
    Cilazaprilat

    Ro 31-3113

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.
    Cilazaprilat
  • HY-B0477A
    Quinapril

    CI-906 free acid

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models .
    Quinapril
  • HY-120663
    KRCA-0713

    		Anaplastic lymphoma kinase (ALK) Cancer
    KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-based experiments. KRCA-0713 was shown to effectively inhibit ALK-driven tumor growth in H3122 xenograft model studies, similar to the effect of ceritinib .
    KRCA-0713
  • HY-157521
    AANAT-IN-1

    		Acyltransferase Endocrinology
    AANAT-IN-1 (compound 30) is a potent inhibitor (IC50: 10μM) of aralkylamine N-acetyltransferase (AANAT). AANAT is responsible for the synthesis of melatonin, which is involved in disorders such as seasonal affective disorder (SAD) in which melatonin levels are abnormally high .
    AANAT-IN-1
  • HY-147720
    γ-Secretase modulator 11

    		γ-secretase Neurological Disease
    γ-Secretase modulator 11 (1o) showed high potency in vitro and brain exposure, inducing brain a β 42 levels were significantly reduced and showed undetectable inhibition of cytochrome P450 enzymes. In addition, compound 1o showed excellent anti cognitive deficit effect in AD model mice.
    γ-Secretase modulator 11
  • HY-163069
    Antitubercular agent-43

    		Bacterial Infection
    Antitubercular agent-43 (compound A11) is an orally active and potent antitubercular agent. Antitubercular agent-43 shows highly metabolic stability against human and mouse cytochrome P450 enzymes. Antitubercular agent-43 exhibits bactericidal efficacy in acute TB infection mouse model .
    Antitubercular agent-43
  • HY-101494
    Temuterkib
    Maximum Cited Publications
    30 Publications Verification

    LY3214996

    		 ERK Cancer
    Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.
    Temuterkib
  • HY-172456
    JSF-4898

    		Bacterial Infection
    JSF-4898 is an orally active inhibitor of the MenG enzyme in Mycobacterium tuberculosis. JSF-4898 has MIC of 0.78 μM against Mycobacterium tuberculosis H37Rv. JSF-4898 can enhance the efficacy of Rifampicin (HY-B0272) in a subacute model of Mycobacterium tuberculosis infection in mice .
    JSF-4898
  • HY-18112
    AZ-4217

    		Beta-secretase Neurological Disease
    AZ-4217 is an inhibitor for β-site amyloid precursor protein cleavage enzyme 1 (BACE1), with IC50 of 160 pM in human SH-SY5Y cells. AZ-4217 reduces amyloid deposition in Tg2576 mouse models, and is used for Alzheimer’s Disease research .
    AZ-4217
  • HY-14923
    Ilepatril

    AVE 7688

    		 Angiotensin-converting Enzyme (ACE) Metabolic Disease
    Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy .
    Ilepatril
  • HY-W150340
    β-Lactose

    		Galectin Biochemical Assay Reagents Cancer
    β-Lactose is a disaccharide commonly found in milk and dairy products. It consists of two monosaccharides, glucose and galactose, linked by β-glycosidic bonds. β-Lactose has various applications in the food industry, especially as a sweetener and bulking agent. Furthermore, it can be used as a substrate for enzymes involved in lactose metabolism and as a model compound for studying carbohydrate-protein interactions.
    β-Lactose
  • HY-120482
    CHM-1-P-Na

    		Microtubule/Tubulin Others
    CHM-1-P-Na is a sodium monophosphate salt of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one, which can be converted into CHM-1, a compound with a unique anti-tumor mechanism, in vitro and in vivo, and has excellent anti-tumor activity in tumor models and clear pharmacological effects on related enzymes.
    CHM-1-P-Na
  • HY-NP009
    α-Lactalbumin

    		Biochemical Assay Reagents Others
    α-Lactalbumin is a Ca 2+-binding protein. α-Lactalbumin has a single strong Ca 2+-binding site and for this reason it frequently serves as a simple model Ca 2+-binding protein. α-Lactalbumin is a component of lactose synthase, an enzyme system, which consists of galactosyltransferase (GT) and α-Lactalbumin .
    α-Lactalbumin
  • HY-B0477AS2
    Quinapril-d4

    CI-906-d4

    		 Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Quinapril-d4 (CI-906-d4) is deuterium labeled Quinapril. Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models .
    Quinapril-d4
  • HY-169061
    WQQ-345

    		Histone Methyltransferase Aminotransferases (Transaminases) Lactate Dehydrogenase Cancer
    WQQ-345 is a BCAT1 inhibitor with an IC50 value of 10.8 mM. WQQ-345 can lead to a decrease in α-KG levels, an upregulation of H3K27me3 expression, a reduction in the expression of glycolytic enzymes (PFKP and LDHA), and impaired glycolytic activity in 67R cells. WQQ-345 shows tumor-suppressing activity in a 67R subcutaneous xenograft model .
    WQQ-345
  • HY-B0130R
    Perindopril (Standard)

    		Angiotensin-converting Enzyme (ACE) NF-κB STAT Sirtuin Cardiovascular Disease Neurological Disease Cancer
    Perindopril (Standard) is the analytical standard of Perindopril. This product is intended for research and analytical applications. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension .
    Perindopril (Standard)
  • HY-146974
    PDE4-IN-9

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PDE4-IN-9 (Compound 5j) is a potent inhibitor of PDE4. PDE4-IN-9 exhibits lower IC50 value (1.4 μM) against PDE4 than parent rolipram (2.0 μM) in in vitro enzyme assay. PDE4-IN-9 also displays good in vivo activity in animal models of asthma/COPD and sepsis induced by LPS .
    PDE4-IN-9
  • HY-N0321
    Caftaric acid

    trans-Caftaric acid

    		 Others Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Caftaric acid (trans-Caftaric acid) is a polyphenolic antidiuretic, antioxidant and anti-apoptotic agent that can be hydrolyzed by intestinal microbial esterases. Caftaric acid exerts its antioxidant and potential anti-inflammatory effects mainly through intestinal microbial metabolism. Caftaric acid can reduce renal damage, restore electrolyte balance, renal function indicators and antioxidant enzyme activities in a rat albinism model, and further exert anti-oxidative stress and anti-inflammatory activities .
    Caftaric acid
  • HY-B0130S1
    Perindopril-d5

    S-9490-d5

    		 Isotope-Labeled Compounds Sirtuin Angiotensin-converting Enzyme (ACE) NF-κB STAT Cardiovascular Disease Neurological Disease Cancer
    Perindopril-d5 (S-9490-d5) is deuterium labeled Perindopril. Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension .
    Perindopril-d5
  • HY-116945
    Diphenamid

    		Endogenous Metabolite Others
    Diphenamid is a chemical compound that exhibits herbicide activity. Diphenamid acts by inhibiting the enzyme acetyl-CoA carboxylase. Diphenamid has shown resistance as a model for mimicking organic pollutants in wastewater treatment processes, especially in the presence of multiple anions. The degradation of diphenamid is significantly affected by certain inorganic ions, such as chromium (VI) and nitrogen oxides. Diphenamid shows changes in toxicity with longer treatment times, and the results of toxicity tests on selected algae indicate higher toxicity at 240 minutes of treatment .
    Diphenamid
  • HY-175735
    Factor XI-IN-2

    		Factor XI Cardiovascular Disease
    Factor XI-IN-2 is a Factor XI activation inhibitor with an IC50 of 20 nM. Factor XI-IN-2 does not directly inhibit the enzymatic activity of FXIa, but specifically binds to the FXI enzyme precursor and allosterically inhibits the process by which it is activated by FXIIa. Factor XI-IN-2 inhibits thrombosis in the rabbit arteriovenous (AV) shunt thrombosis model. Factor XI-IN-2 can be used for the study of antithrombus .
    Factor XI-IN-2
  • HY-168300
    Antiangiogenic agent 7

    		Reactive Oxygen Species (ROS) Apoptosis Inflammation/Immunology Cancer
    Antiangiogenic agent 7 (Compound 1) can induce cell apoptosis, increase Reactive Oxygen Species, and inhibit the intracellular enzyme thioredoxin reductase. Antiangiogenic agent 7 has anti-cancer activity, with an IC50 of 0.08-3.5 μM against cervical cancer cells HeLa, prostate cancer cells PC-3, and non-small cell lung cancer A549. Antiangiogenic agent 7 inhibits tumor growth in mouse xenograft models .
    Antiangiogenic agent 7
  • HY-175023
    OncoACP3

    		Phosphatase Cancer
    OncoACP3 (Compound s43) is a high affinity ligand for prostatic acid phosphatase (ACP3). OncoACP3, radiolabelled with Lu-177, selectively accumulates in enzyme-expressing tumors and shows a potent anti-tumor activity with excellent tumor-selective payload deposition in HT1080.hACP3 and PC3.hACP3 tumor-bearing mice model. OncoACP3 can be used for prostate cancer research .
    OncoACP3
  • HY-116264
    CatB-IN-1

    		Ser/Thr Protease Cancer
    CatB-IN-1 is an enzyme inhibitor with significant inhibitory activity against tumor invasion. CatB-IN-1 may reduce the invasiveness of tumor cells by regulating intracellular protein metabolism. CatB-IN-1 demonstrates effective anti-invasive ability in cell models and can significantly reduce the invasive ability of MCF-10A neoT cells. The structure-activity relationship study of CatB-IN-1 shows that its design can target multiple functions of cat hepsin B .
    CatB-IN-1
  • HY-155726
    Cy-FBP/SBPase-IN-1

    		Others Others
    Cy-FBP/SBPase-IN-1 (compound S5) is a Cy-FBP/SBPase inhibitor, which is an important regulatory enzyme in cyanobacterial photosynthesis. Thus Cy-FBP/SBPase-IN-1 inhibits Calvin cycle and photosystem, and decreases photosynthetic efficiency in cyanobacterial photosynthesis. Cy-FBP/SBPase-IN-1 potently inhibits the growth of cyanobacteria, as well as Synechocystis sp.PCC6803. Cy-FBP/SBPase-IN-1 shows safety profile in human-derived cells and zebrafish models .
    Cy-FBP/SBPase-IN-1
  • HY-175023A
    OncoACP3 TFA

    		Phosphatase Cancer
    OncoACP3 TFA (Compound s43) is a high affinity ligand for prostatic acid phosphatase (ACP3). OncoACP3 TFA, radiolabelled with Lu-177, selectively accumulates in enzyme-expressing tumors and shows a potent anti-tumor activity with excellent tumor-selective payload deposition in HT1080.hACP3 and PC3.hACP3 tumor-bearing mice model. OncoACP3 TFA can be used for prostate cancer research .
    OncoACP3 TFA
  • HY-N7394
    Galbacin

    (3S)-Zuonin A

    		 AMPK Metabolic Disease Cancer
    Galbacin ((3S)-Zuonin A), the epimer of (-)-Zuonin A (HY-N7394A), is a AMPK activator. Galbacin can be isolated from Myristica fragrans (nutmeg). Galbacin stimulates AMPK enzyme in differentiated C2C12 cells. Galbacin also has anticancer activity, and inhibits the proliferation of lymphocyte and tumor cells. Galbacin prevents weight gain in diet-induced mice model. Galbacin can be used for metabolic syndrome (including obesity and type-2 diabetes) and caners research .
    Galbacin
  • HY-16911
    AFN-1252
    10+ Cited Publications

    API-1252; Debio 1452

    		 Bacterial Antibiotic Infection
    AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .
    AFN-1252
  • HY-19109
    RG-7152

    		Leukotriene Receptor Others
    RG-7152 is a tetrazolyl-substituted leukotriene D4 receptor antagonist that can induce peroxisomal β-oxidation and peroxisome bifunctional enzymes (PBEs) in hepatocytes in various animal models. It has been shown to significantly increase PBE levels and β-oxidation activity in rat and mouse liver homogenates, while smaller effects were observed in guinea pigs and monkeys and no effect in dogs. In vitro studies have also shown that it can induce PBEs comparable to clofibric acid, indicating its potential as a peroxisome proliferator .
    RG-7152
  • HY-114622
    AFN-1252 tosylate

    API-1252 tosylate; Debio 1452 tosylate

    		 Bacterial Antibiotic Infection
    AFN-1252 (API-1252) tosylate is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 tosylate exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 tosylate exhibits typical MIC90 values of 0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 tosylate is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .
    AFN-1252 tosylate
  • HY-N2840
    Allitol

    Allodulcitol

    		 Bacterial Drug Intermediate Metabolic Disease Cancer
    Allitol is a rare natural polyol that can be used as a sweetener. Allitol is a sugar alcohol formed by linking D- and L-hexoses in a process called izumoring. Allitol has anti-diabetic effects in a long-term allitol diet rat model. Allitol significantly increases the phylum Bacillota and decreases the phyla Bacteroidetes Actinomycetota, and Pseudomonadota. Allitol significantly increases the levels of butyric acid-metabolizing enzymes in a PICRUSt2 gut microbiota analysis. Allitol is an important intermediate for the preparation of the agents which against diabetes, cancer, and viral infections, including AIDS .
    Allitol
  • HY-146755
    TIY-7

    		Trk Receptor Cancer
    TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC50s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKA G595R, TRKA G667C, TRKA F589L, TRKC G623R, TRKC G696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model .
    TIY-7
  • HY-177295
    Naperiglipron

    LY3549492

    		 GLP Receptor Phosphodiesterase (PDE) Metabolic Disease
    Naperiglipron (LY3549492) (Example 2) is a Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research .
    Naperiglipron
  • HY-12501A
    ITI-214
    3 Publications Verification

    		 Phosphodiesterase (PDE) Neurological Disease
    ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions .
    ITI-214
  • HY-147927A
    (S)-Human enteropeptidase-IN-1

    		Enteropeptidase Metabolic Disease
    (S)-Human enteropeptidase-IN-1 (Compound 6c) is an orally active enteropeptidase inhibitor with low systemic exposure (IC50 (initial): 26 nM; IC50 (app): 1.8 nM). (S)-Human enteropeptidase-IN-1 promotes increased fecal protein output and effectively reduces body weight in a diet-induced obese (DIO) rat model. (S)-Human enteropeptidase-IN-1 inhibits enteropeptidase via a reversible covalent mechanism and prolongs the enzyme inactivation time. (S)-Human enteropeptidase-IN-1 can be used in anti-obesity research .
    (S)-Human enteropeptidase-IN-1
  • HY-12501
    ITI-214 free base

    		Phosphodiesterase (PDE) Neurological Disease
    ITI-214 free base is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 free base inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 free base shows efficacy in various animal models of motor and cognitive functions .
    ITI-214 free base
  • HY-112142A
    (Rac)-AB-423

    DVR-23

    		 HBV Inflammation/Immunology
    (Rac)-AB-423 (DVR-23) is an anti-HBV candidate compound with promising anti-HBV activity. (Rac)-AB-423 showed no induction of CYP1A2, CYP3A4, or CYP2B6 enzyme activity at high concentrations. (Rac)-AB-423 exhibited desirable pharmacokinetic properties, enabling good systemic exposure and high oral bioavailability. (Rac)-AB-423 achieved more than 2 log viral load reduction in the hydrodynamic injection (HDI) HBV mouse model .
    (Rac)-AB-423
  • HY-174811
    PROTAC BRD4 Degrader-33

    		PROTACs Epigenetic Reader Domain PD-1/PD-L1 Inflammation/Immunology Cancer
    PROTAC BRD4 Degrader-33 is an enzyme activated clickable BRD4 PROTAC degrader with favorable tumor microenvironment-response. PROTAC BRD4 Degrader-33 has superior tumor tissue penetration capabilities and efficiently inhibits PD-L1 protein expression. PROTAC BRD4 Degrader-33 shows potent anti-tumoral immunomodulation activity in 4T1 tumor-bearing mice model . Pink: BRD4 ligand (HY-174812); Blue: CRBN ligase ligand (HY-10984); Black: linker
    PROTAC BRD4 Degrader-33
  • HY-P11297
    AC-SDKP-NH2

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research .
    AC-SDKP-NH2
  • HY-155732
    NPD-2975

    		Parasite Infection
    NPD-2975 (compound 30) is an orally active antitrypanosomal agent, against Human African Trypanosomiasis (HAT). NPD-2975 has low toxicity potential against human MRC-5 lung fibroblasts, and acute mouse model of T. b. brucei infection. NPD-2975 shows acceptable metabolic stability, inhibits T. b. brucei with IC500 of 70 nM in vitro. NPD-2975 also inhibits CYP enzymes resulted in IC50 values of 0.16 and 0.42 μM against CYP1A2 and CYP2C19, respectively .
    NPD-2975
  • HY-170846
    FGFRs-IN-1

    		FGFR VEGFR Bcr-Abl FLT3 Cytochrome P450 Inflammation/Immunology
    FGFRs-IN-1 (Compound A16) is the orally active inhibitor for FGFR, that inhibits FGFR1/2/3/4 with IC50s of 2.3, 7, 11, and 163 nM, respectively. FGFRs-IN-1 also inhibits VEGFR1/2/3, Abl, and Flt3 with IC50s of 61, 176, 112, 26, and 353 nM, respectively. FGFRs-IN-1 exhibits weak inhibitory efficacy against CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and inhibits epithelial-mesenchymal transition (EMT) in TGF-β1 stimulated A549 cell. FGFRs-IN-1 exhibits anti-inflammatory activity in Bleomycin (HY-17565)-induced mouse pulmonary fibrosis model and CCl4 (HY-Y0298)-induced mouse liver fibrosis model .
    FGFRs-IN-1
  • HY-15048
    GPI 15427

    		PARP Inflammation/Immunology
    GPI 15427 is a potent inhibitor of the enzyme poly (ADP-ribose) polymerase-1 (PARP-1), which plays a harmful role during inflammation. In a rat model of gut injury and inflammation, including splanchnic artery occlusion (SAO) shock and dinitrobenzene sulfonic acid (DNBS)-induced colitis, GPI 15427 demonstrated strong anti-inflammatory effects. It reduced inflammatory cell infiltration, histological injury, and delayed clinical signs of inflammation. GPI 15427 also diminished the accumulation of poly (ADP-ribose) in the ileum and colon of treated rats. These results suggest GPI 15427 could be useful for treating intestinal ischemia and inflammation .
    GPI 15427
  • HY-149127
    Rosolutamide

    ASC-JM17; ALZ-003

    		 Keap1-Nrf2 Androgen Receptor HSP Mitophagy Metabolic Disease
    Rosolutamide (ASC-JM17), a curcumin analog, is an orally active, potent Nrf1 and Nrf2 activator. Rosolutamide activates Nrf1, Nrf2 and heat shock factor 1 (Hsf1), thereby activating the expression of proteasome subunits, antioxidant enzymes and molecular chaperones. Rosolutamide degrades the polyglutamine (polyQ) androgen receptor (AR) via the ubiquitin-proteasome pathway and improves motor function in mouse models of spinal and bulbar muscular atrophy (SBMA). Rosolutamide improves mitochondrial function and promotes autophagy, decreases mutant protein aggregates, and attenuates intracellular/mitochondrial reactive oxygen species (ROS) levels .
    Rosolutamide
  • HY-N2840R
    Allitol (Standard)

    Allodulcitol (Standard)

    		 Reference Standards Drug Intermediate Bacterial Metabolic Disease Cancer
    D-Tartaric acid (Standard) is the analytical standard of D-Tartaric acid. This product is intended for research and analytical applications. Allitol is a rare natural polyol that can be used as a sweetener. Allitol is a sugar alcohol formed by linking D- and L-hexoses in a process called izumoring. Allitol has anti-diabetic effects in a long-term allitol diet rat model. Allitol significantly increases the phylum Bacillota and decreases the phyla Bacteroidetes Actinomycetota, and Pseudomonadota. Allitol significantly increases the levels of butyric acid-metabolizing enzymes in a PICRUSt2 gut microbiota analysis. Allitol is an important intermediate for the preparation of the agents which against diabetes, cancer, and viral infections, including AIDS .
    Allitol (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: